Latest News about AZN
Recent news which mentions AZN
From Benzinga
2 Top Biotech Stocks to Buy for the Long Haul
August 24, 2022
From Motley Fool
Sorrento Shares Pop After Interim Data From Lung Cancer Trial
August 23, 2022
From Benzinga
From Benzinga
From Best Stocks
From Benzinga
AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report
August 17, 2022
From Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 16, 2022
From Benzinga
3 Top Stocks to Invest In Right Now
August 16, 2022
From InvestorPlace
From Benzinga
UK Government Will Not Buy More AstraZeneca's COVID-19 Treatment
August 16, 2022
From Benzinga
From Benzinga
Why Gilead Sciences Stock Was a 5% Winner Today
August 15, 2022
From Motley Fool
From Benzinga
Landmark Drug Pricing Reform Bill Passes Congress House
August 15, 2022
From Benzinga
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
August 15, 2022
From Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
August 12, 2022
From Benzinga
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
August 12, 2022
From Benzinga
This Analyst Says Zentalis' Increased Focus On WEE1 Program Is 'Prudent', Slashes Price Target By 37%
August 10, 2022
From Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
From Benzinga
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
August 09, 2022
From Benzinga
Recap of Monday's Biotech Catalysts - End Of the Day Summary
August 08, 2022
From Benzinga
AstraZeneca (AZN) Announces Approval of ENHERTU (HER2-low Metastatic Breast Cancer) in the United States
August 08, 2022
Tickers
AZN
From Best Stocks
Lyme Disease And Climate Change Reinvigorates Valneva's Vaccine Efforts After COVID Shot Disappointment
August 08, 2022
From Benzinga
Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders
August 08, 2022
From Benzinga
AstraZeneca's Tagrisso Doublet Therapy Shows 49% Response Rate In Lung Cancer Setting
August 08, 2022
From Benzinga
3 Unstoppable Stocks That Don't Care About the Bear Market
August 07, 2022
From Motley Fool
From MarketWatch
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 04, 2022
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.